+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications



Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications



Recent Advances in Cardiovascular Drug Discovery 10(1): 10-33



Diabetes is a major risk factor for cardiovascular disease, and recent advances in research indicate that a detailed understanding of the pathophysiology of its effects is mandatory to reduce diabetes-related mortality and morbidity. Advanced Glycation End Products (AGEs) play a central role in the genesis and progression of complications of both type 1 and type 2 diabetes mellitus, and have been found to be important even in non-diabetic patients as a marker of cardiovascular disease. AGEs have a profound impact on patient's prognosis regardless of the glycemic control, and therefore pharmacologic approaches against AGEs accumulation have been proposed over the years to treat cardiovascular diseases, parallel to a more detailed understanding of AGEs pathophysiology. Compounds with anti-AGEs effects are currently under investigation in both pre-clinical and clinical scenarios, and many of the drugs previously used to treat specific diseases have been found to have AGE-inhibitory effects. Some products are still in "bench evaluation", whereas others have been already investigated in clinical trials with conflicting evidences. This review aims at summarizing the mechanisms of AGEs formation and accumulation, and the most relevant issues in pre-clinical and clinical experiences in anti-AGEs treatment in cardiovascular research.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057286214

Download citation: RISBibTeXText

PMID: 26530458


Related references

Basic and Clinical Research Against Advanced Glycation End Products (Ages): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications. Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery) 10(1): 10-33, 2016

Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease. Research in Cardiovascular Medicine 4(2): E26949, 2015

Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients. Medical Sciences 6(2), 2018

Fluorophores advanced glycation end products (AGEs)-to-NADH ratio is predictor for diabetic chronic kidney and cardiovascular disease. Journal of Diabetes and Its Complications 29(7): 893-897, 2016

Advanced glycation end products (AGEs) and diabetic vascular complications. Current Diabetes Reviews 1(1): 93-106, 2008

Advanced Glycation End Products (Ages) and Diabetic Vascular Complications. Current Diabetes Reviews 1(1): 93-106, 2005

Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proceedings of the National Academy of Sciences of the United States of America 91(16): 7742-7746, 1994

The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications. Arquivos Brasileiros de Endocrinologia E Metabologia 52(6): 940-950, 2008

Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications. Age 30(4): 303-309, 2009

Food-advanced glycation end products aggravate the diabetic vascular complications via modulating the AGEs/RAGE pathway. Chinese Journal of Natural Medicines 14(11): 844-855, 2017

Advanced Glycation End Products (Ages) and Cardiovascular Disease (Cvd) in Diabetes. Cardiovascular & Hematological Agents in Medicinal Chemistry 5(3): 236-240, 2007

Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. Cardiovascular and Hematological Agents in Medicinal Chemistry 5(3): 236-240, 2007

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology 14: 2, 2016

Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease. Cardiovascular Therapeutics 26(1): 50-58, 2008

Advanced glycation end products and diabetic cardiovascular disease. Cardiology in Review 20(4): 177-183, 2012